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C L I N I C A L R E V I EW
Journal of Feline Medicine and Surgery (2012) 14, 317–326
Nicki Reed and Danièlle Gunn-Moore
NASOPHARYNGEAL DISEASE
IN CATS
2. Specific conditions
and their management
Practical relevance:
Nasopharyngeal disease is
a common presenting problem
in feline medicine.
Clinical challenges: The
management of feline
nasopharyngeal disease can be
challenging at a number of levels. In many cases,
a specific diagnosis may remain elusive. Some
conditions may not be curable so owners need
to understand the requirement for long-term
management. In addition, treatment may be
compromised by poor patient compliance.
Audience: This review, which is directed at any
clinicians involved in the management of cats with
nasopharyngeal disease, discusses acute rhinitis
(cat ’flu) and a variety of conditions causing chronic
rhinosinusitis/chronic nasopharyngeal disease.
The intention is to assist treatment decision making
by reviewing the most appropriate therapies from
the options available for these patients.
Evidence base: The information presented in
this article is based on peer-reviewed publications
and the clinical experience of the authors.
DOI: 10.1177/1098612X12444998
© ISFM and AAFP 2012
Acute rhinitis (cat ’flu)
A number of different respiratory tract infections may give rise to the
clinical signs of acute rhinitis (cat ’flu). Primary infection may be viral
(feline herpesvirus-1 [FHV-1] and calicivirus [FCV]) or bacterial
(Chlamydophila felis, Mycoplasma species, Bordetella bronchiseptica).
In addition, secondary bacterial infection by, for example,
Pasteurella species may complicate viral infections (see Table 1, Part 1).
Clinical signs vary with the causal agent, but generally include sneez-
ing, nasal discharge, anorexia, pyrexia, conjunctivitis, ocular discharge,
and oral and/or ocular ulceration. The severity of signs is dependent
on the pathogenicity of the causal organism, and on the immune
response of the cat. Nasal discharge is usually bilateral, and may
initially be serous, progressing to mucopurulent in nature (Figure 1).
Thick, tenacious nasal discharge may cause upper airway obstruction,
resulting in a prolonged inspiratory phase and noticeable upper respi-
ratory noise. The presence of nasal discharge may lead to ulceration
of the nares with chronicity.
Identification of a causal agent
may help with management.
Antibacterial therapy
Broad spectrum antibacterials are
generally prescribed to prevent
establishment of bacterial infec-
tion secondary to viral damage
(Table 1). If Mycoplasma, Chlamy-
dophila or Bordetella species are
identified, tetracyclines (in par-
ticular doxycycline) are consid-
ered the treatment of choice.
Good responses are also seen
with fluoroquinolones or azithro-
PART 1
Part 1 of this two-part article, which
addresses the investigation of
nasopharyngeal disease in order to obtain
a diagnosis, appears on pages 306–315
of this issue of J Feline Med Surg and at
DOI: 10.1177/1098612X12444997
Nicki Reed
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European Veterinary Specialist in Internal Medicine*
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Figure 1 Mucopurulent nasal discharge
in a cat with FHV-1 infection
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Drug Dose Indications Comments
A
nt
ib
ac
te
ri
al
s
Amoxicillin–
clavulanate
12.5–20 mg/kg
q8–12h PO, IV, SC
Gram +ve aerobes
Gram –ve aerobes
Obligate anaerobes
Not effective against Mycoplasma; variable efficacy against
Pseudomonas and Chlamydophila
Doxycycline 10 mg/kg q24h PO Chlamydophila
Mycoplasma
Bordetella
Can cause oesophagitis – give with food or follow with
5 ml water; can cause tooth discoloration in young animals;
do not give to pregnant animals
Marbofloxacin 2 mg/kg q24h PO, IV Mycoplasma, Chlamydophila,
Bordetella, Pseudomonas,
Pasteurella, Staphylococcus,
Escherichia coli
Give following culture results; cartilage abnormalities in
young animals; risk of retinal blindness; do not give to
pregnant or lactating animals or those with epilepsy
Pradofloxacin 3–5 mg/kg q24h PO Mycoplasma, Chlamydophila,
Bordetella, Pseudomonas,
Pasteurella, Staphylococcus,
Escherichia coli
As for marbofloxacin except that retinal blindness has not
been reported. Doses as high as 10 mg/kg have been used
without evidence of side effects1
Clindamycin 5.5–11 mg/kg q12h PO, IV Gram +ve aerobes
Anaerobes
Mycoplasma
Can cause oesophagitis – give with food or follow with
5 ml water
Erythromycin 10–20 mg/kg q8–12h PO Gram +ve cocci, Pasteurella,
Mycoplasma, (Chlamydophila)
Gastrointestinal upset common side effect
Variable efficacy against Chlamydophila
Azithromycin 5 mg/kg q48h PO Gram +ve cocci and bacilli,
Pasteurella, (Chlamydophila),
Mycoplasma, Bordetella
Pseudomonas usually resistant
Variable efficacy against Chlamydophila
A
nt
iv
ir
al
s
Famciclovir 5–20 mg/kg q8h PO2
90 mg/kg q8h PO3
FHV-1 Optimal dose yet to be decided
L-lysine 250 mg/kitten q12h PO
500 mg/cat q12h PO
FHV-1 – reduction of clinical signs
and viral shedding
Efficacy not proven; products should not contain propylene
glycol as preservative
Interferon ω 1 MU/kg SC q24–48h
50,000–100,000 U PO q24h
FHV-1
FCV
No controlled studies; can be used alongside L-lysine
Interferon α 5–35 U q24h
SC – high dose
PO – low dose
FHV-1
FCV
No controlled studies; can be used alongside L-lysine;
SC administration can lead to antibody formation
A
nt
ifu
ng
al
s
Fluconazole 50 mg/cat q12–24h Cryptococcus species; mycotic
infections involving the central
nervous system (CNS)
Several weeks/months of treatment may be required;
do not administer to pregnant animals; dose reduction
in patients with renal disease. Treat until LCAT (latex
cryptococcal antigen agglutination test) titre is zero
Itraconazole 5–20 mg/kg q24h PO Mycotic infections not
penetrating the CNS
Several weeks/months of treatment may be required; do not
administer to pregnant animals; many drug interactions.
Monitor liver enzymes – may cause hepatotoxicity
Voraconazole 10 mg/kg q24h PO Cryptococcus species
Aspergillus species
Several weeks/months of treatment may be required;
do not administer to pregnant animals; neurological
abnormalities reported
Ketoconazole 5–10 mg/kg q12h PO Cryptococcus species Several weeks/months of treatment may be required; do not
administer to pregnant animals; use generally superseded
by other drugs; hepatotoxicity; many drug interactions
Amphotericin B 0.5 mg/kg in 350 ml 0.45%
saline and 2.5% dextrose
SC one to three times
weekly4
Cryptococcus species –
including CNS infection;
Aspergillus species
Nephrotoxic – toxicity reduced by use of liposome-
encapsulated or lipid-complex formulations. Infuse in saline
or DW5, as incompatible with lactated Ringer’s.
Monitor renal function
Flucytosine 30–75 mg/kg PO q6–12h Cryptococcus species –
including CNS infection
Synergistic with amphotericin B; resistance develops if used
alone
Clotrimazole Topical infusion (~20 ml) Aspergillus species Hour long infusion5,6
M
is
ce
lla
ne
o
us
Meloxicam 0.1 mg/kg PO q24h Pain/inflammation associated
with chronic rhinitis
Adenocarcinoma?
Risk of renal, hepatic and gastrointestinal toxicity
Piroxicam 0.3 mg/kg PO q48–72h Adenocarcinoma? Risk of renal, hepatic and gastrointestinal toxicity
Ciclosporin 5–10 mg/kg q24h Allergic rhinitis? Chronic rhinitis?
Zafirlukast 0.5–1 mg/kg PO q12–24h Allergic rhinitis? Chronic rhinitis?
Montelukast 0.25–0.5 mg/kg PO q24h Allergic rhinitis? Chronic rhinitis?
PO = orally, IV = intravenously, SC = subcutaneously, DW5 = 5% dextrose in water
While every effort has been made to ensure correct doses are given, the authors advise independent verification of doses prescribed
Many drugs listed do not have a veterinary product licence
Medications used in the management of nasopharyngeal disease in catsTable 1
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Chronic rhinosinusitis/
chronic nasopharyngeal disease
Nasal neoplasia
Neoplasia is the most common cause
of nasopharyngeal disease in cats.17,18
Lymphoma is the most common tumour
affecting the nasal cavity (29–70% of neo-
plasms), followed by adenocarcinoma
(13–15%). Carcinomas (squamous cell, undif-
ferentiated) and sarcomas (fibrosarcoma,
osteosarcoma, chondrosarcoma) are less com-
monly reported, along with various other neo-
plasms.18,19 Stertor, nasal discharge (including
epistaxis) and facial deformity are typical
presenting signs. Neurological signs, includ-
ing seizures, may be seen with extension of
the disease through the cribriform plate.
Lymphoma
Nasal lymphoma typically affects middle-
aged to older cats, with mean ages of 8.9 and
11.4 years, and a range of 3–17 years, report-
ed.20,21 Male cats may be at increased risk com-
pared with female cats, comprising up to 79%
of the study population.5,19,21 Siamese cats are
potentially overrepresented, comprising up
to 14% of cases,5,19,21 although the reported
prevalence was not compared with the refer-
ence population. It is, however, in keeping
with previous studies, which have suggested
that Siamese cats are predisposed to lym-
phoma in general.22
Nasal lymphomas show B cell predomi-
nance, with 68–100% of tumours reported as B
cell immunotype,19–21 although epitheliotropic
nasal lymphomas have also been reported.19
Most (90%) feline nasal lymphomas are
mycin.7,8 However, as these infections often
occur in young kittens where the side effects
of these antibacterials may be undesirable
alternative choices may be needed. A good
alternative for the treatment of Chlamydophila
species infection is amoxicillin–clavulanate.9
Mycoplasma species do not have a cell wall,
rendering β lactam antibiotics ineffective.
For the treatment of these infections
macrolides such as erythromycin and
azithromycin may be sensible alternatives;
however, resistance to these drugs is rapidly
emerging with humanMycoplasma pneumoniae
infections.10 Although not licensed for veteri-
nary use, azithromycin has the advantage that
it comes in a liquid formulation, which may
be easier to administer and enables accurate
dosing, particularly for small kittens. No
veterinary studies have been performed to
test the efficacy of azithromycin against
Bordetella bronchiseptica, although human
strains of Bordetella pertussis are susceptible.11
Although azithromycin alleviated clinical
signs of Chlamydophila species in one feline
study, it did not result in clearance of the
infection,12 and in a second study there was no
improvement in respiratory signs in shelter
cats treated with azithromycin compared with
amoxicillin.13
Antiviral therapy
If FHV-1 is identified then famciclovir
has been demonstrated to reduce clinical
disease.2,3 The use of L-lysine in cases of
FHV-1 is controversial. It may be of benefit
in reducing clinical signs and shedding of
the virus, but administration of tablets is
more beneficial than administering it in food,
and as such the stress of pilling has to be
weighed up against the benefit.14 Although
feline interferon omega was associated with
decreased viral replication in vitro,15 no
significant differences were found when this
drug was used in the management of FHV-1
infected cats in vivo.16 Similarly, there are no
published studies demonstrating benefit of
interferon (human or feline recombinant) in
the management of rhinitis associated with
FCV.
Supportive treatment
Supportive treatment with good nursing care
is required for these patients, which are
anorectic and dehydrated. Fluid therapy may
be indicated, and syringe feeding or tube
feeding may be required as the inability to
smell food will affect appetite. Nasal dis-
charges should be removed by bathing – neb-
ulisation with saline may facilitate clearance
of nasal discharge. Analgesia may be indicat-
ed where sinus pain is present, and some
authors recommend decongestants.
Figure 2 Nasopharyngeal
lymphoma. (a) Soft tissue
mass in the right
nasopharynx, causing loss
of turbinate detail and
bowing of the nasal septum.
(b) The mass in the
nasopharynx,
as viewed by retroflexed
endoscopy. (c) The mass
removed by forced flush
of the right nasal cavity.
(d) Cytology of an
impression smear made
from the mass, showing
predominance of round
cells, suggestive of
lymphoma (confirmed by
histopathology). Diff Quik
x 400
a
b
c d
Neoplasia
is the most
common cause
of chronic
nasopharyngeal
disease in cats,
with lymphoma
being the most
frequently
identified
tumour.
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Although a large number of dif-
ferent types of tumour have been
reported, the most commonly
encountered are adenocarcino-
ma, undifferentiated carcinoma,
squamous cell carcinoma and
fibrosarcoma.19Adenocarcinomas
may be subdivided into four
types – acinous, cystic, mucinous
and papillary (Figure 3).19
Radiotherapy is considered
the treatment of choice, with
median survival times of 382
days reported.25 Treatment of
adenocarcinoma with piroxicam
and chemoembolisation has also
been reported.26 The theoretical benefit of
piroxicam is based on the presence of COX-2
expression in tumours. One study to assess
the presence of COX-2 in various feline neo-
plasms did not identify expression in nasal
tumours.27 However, all the nasal tumours in
this study were lymphomas; therefore, the
expression of COX-2 in epithelial nasal
tumours has yet to be investigated.
Chronic rhinosinusitis
The majority of cases of chronic upper respira-
tory tract disease are defined as chronic post-
viral rhinitis/sinusitis. The initial viral infec-
tion causes damage to the nasal mucosa, which
allows secondary infection with oropharyn-
geal bacteria, and hence the establishment of
chronic osteomyelitis of the turbinate bones.
However, FHV-1 and FCV are very prevalent
in the general feline population, and latent
infection is relatively common; as it may not
be possible to detect FHV-1 or FCV at this late
stage of disease, the condition should more
correctly be termed chronic rhinosinusitis.
Chronic rhinosinusitis is rarely curable so
the emphasis is onmanagement to improve the
patient’s quality of life (see box on page 321).6
Allergic rhinitis
Some cases of chronic nasal discharge may be
suspected to be allergic in origin on the basis
of an eosinophilic or lymphoplasmacytic infil-
trate being identified on nasal biopsy, or
concurrent asthma-like signs. However, as the
underlying allergic trigger is rarely identified,
as with chronic rhinosinusitis, therapeutic
strategies aim for management rather than
cure. Glucocorticoids may be indicated if
allergic rhinitis or lymphoplasmacytic rhinitis
is present. Inhaled forms may be preferable to
systemic administration, due to the reduced
risk of systemic side effects. Topical steroid
nasal drops are rarely well tolerated by cats.
Ciclosporin or antileukotriene medications
(zafirlukast, montelukast) may be considered
if the systemic side effects of corticosteroids
classified as high grade20 and,
although traditionally thought of
as being localised to the nasal
cavity, one study identified that
in 67% of cats in which a post-
mortem examination was carried
out, extension of the disease was
present.20 Numerous locations,
including lymph nodes, intestine,
spleen, liver and kidney, are
reported, but local extension was
also identified in this and another
study.23 Diagnosis is based on
histopathology, although cytol-
ogy from impression smears can
be supportive of the diagnosis
(Figure 2).
Treatment options comprise radiation thera-
py or chemotherapy (COPor CHOPprotocols).
Debulking of the mass (eg, by forced flush)
may improve clinical signs where these thera-
pies are declined. The prognosis without treat-
ment or with prednisolone alone is generally
poor, with a reported median survival of only
22 days.21 Chemotherapy with the COP pro-
tocol has had variable reported success.
Henderson et al18 described a median survival
time of only 98 days, whereas in a study by
Teske et al24 75% of cats were still alive at 1 year.
The reported response to radiation therapy
appears to be better, with a median survival of
40.8 months based on seven cats.21 The combi-
nation of radiation therapy and chemotherapy
did not appear to improve the outcome, with a
median survival for 19 cats of 955 days.21 A sec-
ond, retrospective study also failed to identify
significant differences between treatment with
chemotherapy, radiation or chemotherapy and
radiation, with a median survival time, regard-
less of treatment modality, of 536 days.5 This is
perhaps surprising in the light of the frequency
of systemic involvement previously reported,
as radiation therapy alone would not treat dis-
seminated disease.
Cats in which the cribriform plate was
destroyed had a poorer prognosis in the study
by Sfiligoi et al,21 but not in another.5 The
presence of anaemia has also been identified
as a poor prognostic factor.5 Dichotomous
populations are identified, with cats that
fail therapy early and survive less than 6
months, and those that experience remission
and go on to have a prolonged survival.5,21
Further work is required to determine factors
that predict a good prognosis and the best
form of therapy.
Non-lymphoid neoplasia
Non-lymphoid neoplasia of the nasal cavity is
far less common than lymphoid neoplasia.
Epithelial tumours (carcinomas) are more com-
mon than non-epithelial tumours (sarcomas).
Figure 3 Mucinous
adenocarcinoma. Post-
mortem examination
of a 17-year-old domestic
shorthair cat with mucinous
adenocarcinoma occupying
the right nasal cavity (nasal
and frontal bones removed).
The mass eroded through
the cribriform plate into the
olfactory bulb. The diagnosis
had been established 6
months earlier and the cat
had been managed with oral
meloxicam. Clinical signs
(sneezing and epistaxis) had
been present for 5 months
prior to diagnosis.
Courtesy of L Morrison
Chronic
rhinosinusitis
is the most
common
condition
affecting the
more rostral
nasal cavity.
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are not tolerated. No clinical trials have been
conducted to establish the efficacy and safety
of these off-licence drugs. It is also important
to address the cat’s environment, with regard
to reducing exposure to allergens (eg, dust
from cat litter, smoke, aerosols, etc).
Fungal rhinitis
Fungal rhinitis in cats is primarily attributed
to cryptococcal (Cryptococcus neoformans and
Cryptococcus gattii) infection.4 Cryptococcosis
is seen worldwide; however, it is rare in the
UK, and only comprised 4% of cases in a
study conducted in the USA.30Other causes of
fungal rhinitis include Aspergillus species31–34
and Penicillium species,31,32 with occasional
case reports of hyalohyphomycosis (Scedo-
sporium apiospermum or Fusarium species
infection), trichosporonosis (Trichosporon lou-
bieri infection), and Metarhizium anisopliae and
Alternaria species infections.32,35–39
Clinical signs typically consist of nasal
discharge (± epistaxis), sneezing, stertorous
respiration and/or facial swelling. Turbinate
lysis is frequently identified on computed
tomography.33 The pathophysiology, diagno-
sis and treatment of feline cryptococcosis have
been reviewed recently.4 A number of drugs
have been employed in the treatment of
cryptococcosis (Table 1), but fluconazole is an
appropriate first choice due to minimal side
effects and good penetration into the brain in
cases with local extension.4 Treatment efficacy
may be assessed by monitoring serology titres
for cryptococcal capsular antigen until the titre
reaches zero.4 Treatment of other causes of
fungal rhinitis has comprised intranasal clotri-
mazole infusion,31,38 oral itraconazole,31,32,36,37
surgical debridement with topical (enilcona-
zole) and systemic (itraconazole) therapy35
and oral voriconazole.40
Fungal rhinitis warrants a guarded progno-
sis, particularly if there is local extension of the
disease into the CNS.41 These cases may benefit
from combination fluconazole and subcuta-
neous amphotericin B therapy.42 While 60% of
cases of cryptococcosis in one study appeared
to be cured, some cases that initially responded
to therapy subsequently relapsed.41 Owners,
therefore, need to be warned of the potential
for recurrence of clinical disease (Figure 4).
Figure 4 Aspergillus infection. (a) Nasal
catheters placed for clotrimazole infusion (a
third catheter is also placed in the nasopharynx).
(b) Branching hyphae of Aspergillus (new
methylene blue stain x 100). (c) The cat following
rhinotomy and curettage, required to clear the
fungal infection. Courtesy of A Ridyard
Man a g eme n t o f c h r o n i c r h i n o s i n u s i t i s
ﬁ Antibiotics Biopsies of the nasal turbinates usually reveal
neutrophilic or lymphoplasmacytic rhinitis, and occasionally
eosinophilic inflammation.28 Periodic courses of antibiotics often
need to be given. These cases should be treated as for
osteomyelitis, with prolonged (6–8 weeks)
courses of antibiotics with good penetration
into bone, and ideally with efficacy against
anaerobes, as these organisms are
frequently identified.29 Preferably, antibiotic
selection should be based on culture
and sensitivity testing following a deep
nasal flush. Clindamycin and amoxicillin–
clavulanate can be used, but some cases
require doxycycline or fluoroquinolones due
to the infectious agent present.
ﬁ Anti-inflammatories Some cats may
require therapy to reduce airway inflammation. Non-steroidal anti-
inflammatories may be appropriate if there is concern about the
presence of an infectious process, although the patient
should be adequately hydrated and eating.
ﬁ Therapeutic flush A therapeutic flush entails adding an
antibiotic, antiseptic or other therapeutic agent (eg, interferon)
to the intranasal flush. This may have beneficial effects when
performed at the end of a nasal investigation. Even removal of
large volumes of mucus by flushing with
saline often results in clinical improvement in
the short to medium term.
ﬁ Nasal curettage Nasal curettage should
not be undertaken lightly. While this
procedure results in a degree of
improvement in some cases, other cases
benefit little. In addition, the procedure can
be very painful; postoperative analgesics are
essential.
ﬁ Frontal sinus ablation, trephination
and irrigation This approach may be
considered where inflammation has extended into the frontal
sinuses. The response is not always favourable and
postoperatively the patient can be in considerable pain.
Analgesics are essential.
a
b
c
Chronic rhinosinusitis
is rarely curable
so the emphasis
is on management
to improve the
patient’s quality of life.
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Nasopharyngeal polyps
Nasopharyngeal polyps are benign, inflam-
matory growths arising from the lining of
the middle ear or the Eustachian tube. They
are comprised of fibrovascular connective tis-
sue covered by stratified squamous or ciliated
columnar epithelium.43 The polyps may
extend into the pharyngeal area (nasopharyn-
geal polyps) and typically be accompanied by
respiratory signs, or through the tympanic
membrane into the external ear canal (aural
polyps) and typically be accompanied by
signs of otitis externa. Nasopharyngeal polyps
usually occur in young cats, although an
age range of 3 months to 15 years is recorded.
In studies of nasopharyngeal disease the
frequency of polyps has ranged from
1.3–28%.17,18,30 However, these studies were
based on referral populations, which may not
reflect the true prevalence of this disease in
the general population. The authors’ clinical
experience would suggest this condition is
rare.
The aetiology of nasopharyngeal polyps is
incompletely understood. Their predomi-
nance in young cats has led to one theory that
they may be a congenital abnormality of the
first pharyngeal pouch, from which the
Eustachian tube and the middle ear cavity
derive.43 An alternative theory is that they
arise as a result of chronic inflammation of
the middle ear, either due to respiratory tract
infection or to otitis externa attributed to, for
example, infestation with Otodectes cynotis.42
Although some cats have a history of upper
respiratory tract infection or ear mite infesta-
tion prior to diagnosis, not all cases do. A
recent study failed to demonstrate a consis-
tent association between infectious agents
(FCV, FHV-1, Mycoplasma species or
Chlamydophila species) and the presence of
nasopharyngeal polyps.44 The presence of
inflammation is proposed to affect Eustachian
tube function, resulting in inadequate middle
ear ventilation and decreased middle ear
pressure. The combination of mucociliary
dysfunction and hypersecretion of mucus
contribute to effusion within the middle ear,
which may or may not lead to bacterial con-
tamination and the development of inflamma-
tory granulation tissue.45
Clinical signs associated with nasopharyn-
geal polyps include stertor, nasal discharge
and dysphagia. The nasal discharge is usually
serous in nature, unless secondary bacterial
infection is present. Dysphagia may lead to
weight loss or failure to thrive in young kit-
tens. Initial presenting signs may be attributed
to respiratory tract infection, although sneez-
ing and coughing are infrequently reported.
Altered phonation is occasionally described.
The presence of a mass within the middle ear
Figure 5 Nasopharyngeal polyp in a young adult cat. (a) Ventral bowing of the soft palate due
to a mass lesion dorsally within the nasopharynx. (b) Lateral radiograph showing a soft tissue
opacity dorsal to the soft palate (arrow). (c) Nasopharyngeal polyp following removal by
traction. Note the long narrow stalk. (d) Presence of right-sided Horner’s syndrome following
removal of the nasopharyngeal polyp. Signs improved after 48 h
may lead to signs of head shaking or Horner’s
syndrome. If the polyp progresses into the
inner ear, vestibular signs such as nystagmus,
head tilt and ataxia may be present. Signs
may have an insidious onset and be present
for some time before veterinary attention is
sought. Ventral deviation of the soft palate
may be noted on intraoral examination
(Figure 5a), or a mass lesion may be detected
on otoscopic examination. Radiography may
demonstrate soft tissue masses within the
nasopharynx, dorsal to the soft palate, or
opacification of the tympanic bulla (Figure
5b).
Treatment options are discussed in the box
on page 323.
Inflammatory polyps of the
nasal turbinates
Inflammatory polyps of the nasal turbinates
were previously considered to be a rarer
manifestation of nasopharyngeal polyps.
However, more recent work suggests that
these should be considered separately, as they
arise from the nasal turbinates, rather than the
Eustachian tube.48 In addition, their histologi-
cal appearance is consistent with that of
mesenchymal nasal hamartoma,48 rather than
being comprised of fibrovascular tissue with
a stratified squamous or ciliated columnar
epithelium. The condition appears to be more
common in Italy, which may relate to genetic
a b
c d
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or environmental factors.48 Only one case has
been reported from the UK.49 This involved
a Russian Blue cat and, although there is no
documented breed predisposition, the
authors’ experience is that this condition is
more common in Oriental breeds of cat.
Clinical signs may comprise stertor, sneez-
ing, open-mouth breathing, serous nasal
discharge, epiphora and epistaxis. In addition,
mass lesions may be seen protruding from
the nostrils. Radiographic studies typically
demonstrate soft tissue opacification of the
rostral nasal cavity. With high detail, more
radiolucent areas may be seen, corresponding
to cystic spaces within the lesion.48 Although
spontaneous regression has been reported,
lesions are more typically removed,
either endoscopically or, for more extensive
lesions, by rhinotomy to facilitate complete
excision.48,49
Tr e a tm e n t o p t i o n s f o r n a s o p h a r y n g e a l p o l y p s
Traction/avulsion
Traction/avulsion is generally the simplest form of treatment,
requiring minimal equipment. With the cat in dorsal recumbency
the polyp is grasped with Allis forceps and traction applied until
the polyp detaches at its stalk (Figure 5c). Minor haemorrhage
can be expected following this procedure, but it either stops
spontaneously or can generally be managed with pressure appli-
cation to the palatine area. Access to the polyp may be facilitat-
ed by application of pressure to the soft palate, displacing the
mass caudally, or by retracting the palate rostrally with a spey
hook or placement of stay sutures. Alternatively, more direct
access over the mass may be achieved via a midline incision in
the soft palate (avoiding the distal 5 mm), retracting the edges of
the incision with stay sutures. The polyp is again removed by
traction and the soft palate is repaired with an absorbable
suture. The main complications following this procedure include
recurrence and development of Horner’s syndrome (Figure 5d).
The latter has been reported in 43% of cases treated by trac-
tion,46 with signs usually resolving within 1 month.
Recurrence rates of up to 41% have been reported following
removal by traction alone,46 although recurrence was more fre-
quent with aural polyps than nasopharyngeal
polyps. Recurrence is more likely in cases that
have radiographic evidence of bulla involve-
ment; that said, 30% of cases with bulla
disease were treated successfully by traction
alone.46 Anti-inflammatory doses of pred-
nisolone administered for 4 weeks postopera-
tively significantly improved outcome.46 Polyp
recurrence has been reported to occur from
19 days to 9 months postoperatively.
Ventral bulla osteotomy
Ventral bulla osteotomy has been proposed
by some authors to be the treatment of
choice due to the high incidence of middle ear
involvement.47 With the cat in dorsal recum-
bency, access to the ventral bulla is
obtained with a Steinmann pin and rongeurs,
allowing the contents of the bulla to be
sampled and the inflammatory tissue to be
removed with a curette (Figure 6). Polyp recur-
rence rates are considered to be lower than for
traction/avulsion, but the technique carries greater risks. Care
must be taken not to damage the lingual artery, hypoglossal
nerve or tympanic plexus. Postoperative complications include
a higher risk of development of Horner’s syndrome (57%),46
and the potential to develop vestibular disease or facial nerve
paralysis.
Total ear canal ablation/lateral bulla osteotomy;
myringotomy/lateral wall resection
These procedures are not generally required for nasopharyngeal
polyps, but may be required for aural polyps. They are expensive
and carry a higher risk of morbidity. Surgical textbooks should
be consulted or referral to a specialist surgeon considered if
these procedures are felt to be warranted.
Figure 6 Ventral bulla osteotomy. (a) Removal of inflammatory material from the bulla by use
of a curette (white arrow). (b) Appearance of the bulla after removal of inflammatory material,
showing the larger ventromedial compartment (stippled arrow) and the smaller dorsolateral
compartment (black arrow). Courtesy of A J Tattersall
a b
Nasopharyngeal stenosis
Nasopharyngeal stenosis is a relatively
uncommon condition, accounting for 5/77
cases of nasal disease in one study,30 and 0/75
cases in a second.18 In this condition, the
nasopharynx is occluded by a membrane,
which is thought to form secondarily to a
process that triggers scar formation (Figure 7).
Examples include trauma, infectious diseases
or vomiting with aspiration of gastric contents
into the nasopharynx. A recent case report
described the finding of hiatal hernia and
megaoesophagus secondary to the presence of
nasopharyngeal stenosis.50
The stenotic membrane may be seen radio-
graphically as a thin soft tissue opacity within
the nasopharynx, dorsal to the soft palate
(Figure 7a,b), which is sometimes accompa-
nied by dorsal deviation of the soft palate at
the site of attachment.51,52 Retroflex endoscopy
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administration of a course of systemic cortico-
steroids may reduce the risk of recurrence.
Alternative options for management of
nasopharyngeal stenosis include forceps dilata-
tion,18 mucosal advancement flap surgery,52 or
placement of a stent.54 Despite the potential for
recurrence, the prognosis is generally good.
Foreign bodies
Foreign bodies are reported to be the third
most common cause of nasal disease in cats.30
Plant material (grass blades, awns, seeds) is
most commonly documented;30,55 surprisingly
this may sometimes be detected radiographi-
cally, providing the material does not abut the
soft palate (Figure 8). Radiopaque material
such as stones, needles and air-gun pellets
may also be identified,30 and a recent report
described a nasopharyngeal trichobezoar
with the radiographic appearance of a soft tis-
sue mass.56 Foreign material may be inhaled,
or vomited/coughed up into the nasopharynx.
Cats with more rostral foreign bodies will
typically present with nasal discharge, where-
as foreign bodies in the nasopharynx typically
produce retching, gagging and stertorous
respiration. Purulent nasal discharge and
halitosis may develop, particularly with
chronicity. Removal usually necessitates visu-
alising the foreign body and grasping it with
forceps. Barbs on grass blades or plant awns
can make this problematic, and flushing of the
nasal passages may assist with removal.
Larger foreign bodies may be removed using
forced flushing or may be pushed into
the pharynx following the insertion of a stiff
urinary catheter into the nasopharynx from
the nares.
demonstrates a narrow lumen into the
nasopharynx and an inability to view the
choanae (Figure 7c). If endoscopic evaluation
is not possible, contrast radiography51 or fail-
ure to pass nasal catheters into the nasophar-
ynx52 may further support the diagnosis.
Balloon dilatation is usually used to break
down the stenotic membrane (Figure 7d,e). The
balloon catheter is introduced in a normograde
fashion from a nostril and its placement verified
either with fluoroscopy or simultaneous
retroflexed endoscopy of the nasopharynx.51,53
Repeated procedures may be required due to
reformation of the stenotic membrane;51,53
Figure 7 Nasopharyngeal
stenosis. (a) Lateral
radiograph of a cat showing
a membrane of soft tissue
dorsal to the soft palate.
(b) Highlighted region of
nasopharyngeal stenosis.
(c) Retroflexed endoscopic
appearance of the stenotic
nasopharynx. (d) Retroflexed
endoscopic appearance of
the nasopharynx following
balloon dilatation. (e) Balloon
catheter with manometer to
monitor pressure exerted on
the balloon
Figure 8 Nasopharyngeal foreign body. A radiopaque line can be seen dorsal and parallel to
the soft palate. (inset) The foreign body was a blade of grass
a b
c d e
ﬁ Chronic rhinosinusitis and
neoplasia are the two
most common causes of
nasopharyngeal disease in cats.
ﬁ The underlying aetiology in cats
with chronic rhinosinusitis is rarely
identified, but the condition is
speculated to be associated with
previous viral damage.
ﬁ Chronic rhinosinusitis can be
frustrating to manage.
ﬁ Neoplastic disease is more frequently
identified in middle-aged to older cats,
and carries a varied prognosis.
ﬁ Foreign bodies, nasopharyngeal polyps
and nasopharyngeal stenosis can be
rewarding to treat, with a cure effected
in the majority of cases.
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